Blueprint二期:真实临床肺癌样本中PD-L1免疫组化检测可比性研究
Blueprint二期项目采用81例真实世界肺癌标本,以五种PD-L1免疫组化检测(22C3、28-8、SP142、SP263、73-10)染色并由国际病理专家组评估。结果显示22C3、28-8与SP263染色高度可比,SP142敏感性较低,73-10对肿瘤细胞PD-L1检测敏感性更高;玻片与数字图像评分高度一致,肿瘤细胞评分病理医师间可靠性很强,免疫细胞评分可靠性差。
要点
- 22C3、28-8与SP263三种PD-L1检测在肿瘤细胞评分上高度可比,可互换使用。
- SP142检测肿瘤细胞PD-L1敏感性较低,73-10敏感性高于其他检测。
- 肿瘤细胞PD-L1评分病理医师间可靠性很强,免疫细胞评分可靠性差。
核心结论
- Blueprint二期巩固了22C3、28-8与SP263检测可互换的分析证据,并证实SP142对肿瘤细胞比例评分敏感性较低、73-10敏感性高于其他检测。
研究设计与样本
- Blueprint二期采用81例不同组织学与样本类型的真实世界肺癌标本,以五种试验验证的PD-L1检测(22C3、28-8、SP142、SP263、73-10)染色,由国际病理专家组评估。
- 研究同时评估了数字图像评分与细胞学检查样本的可靠性。
主要发现
- 22C3、28-8与SP263检测染色高度可比;SP142敏感性较低;73-10对肿瘤细胞PD-L1表达检测敏感性更高。
- 玻片与数字图像评分高度一致(Pearson相关系数>0.96)。
- 所有检测的肿瘤细胞PD-L1评分病理医师间总体组内相关系数为0.86-0.93,免疫细胞PD-L1评分总体组内相关系数为0.18-0.19,细胞学细胞块材料PD-L1状态评估组内相关系数为0.78-0.85。
关键数值与推荐
- PD-L1表达按肿瘤细胞与免疫细胞区域染色百分比评估,肿瘤细胞连续或按检查点抑制剂试验所用截断值分类评分。
- 玻片与数字图像评分Pearson相关系数>0.96;肿瘤细胞评分总体组内相关系数0.86-0.93;免疫细胞评分总体组内相关系数0.18-0.19;细胞学细胞块评估组内相关系数0.78-0.85。
临床怎么用
- 临床选择PD-L1检测时,可依据Blueprint二期结果在22C3、28-8与SP263之间考虑互换使用。
- 对SP142与73-10的肿瘤细胞评分结果解读需注意其敏感性差异。
- 肿瘤细胞PD-L1评分可靠性高,免疫细胞评分可靠性差,细胞学细胞块材料可用于PD-L1状态评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The Blueprint (BP) Programmed Death Ligand 1 (PD-L1) Immunohistochemistry Comparability Project is a pivotal academic/professional society and industrial collaboration to assess the feasibility of harmonizing the clinical use of five independently developed commercial PD-L1 immunohistochemistry assays. The goal of BP phase 2 (BP2) was to validate the results obtained in BP phase 1 by using real-world clinical lung cancer samples. METHODS: BP2 were conducted using 81 lung cancer specimens of various histological and sample types, stained with all five trial-validated PD-L1 assays (22C3, 28-8, SP142, SP263, and 73-10); the slides were evaluated by an international panel of pathologists. BP2 also assessed the reliability of PD-L1 scoring by using digital images, and samples prepared for cytological examination. PD-L1 expression was assessed for percentage (tumor proportional score) of tumor cell (TC) and immune cell areas showing PD-L1 staining, with TCs scored continuously or categorically with the cutoffs used in checkpoint inhibitor trials. RESULTS: The BP2 results showed highly comparable staining by the 22C3, 28-8 and SP263 assays; less sensitivity with the SP142 assay; and higher sensitivity with the 73-10 assay to detect PD-L1 expression on TCs. Glass slide and digital image scorings were highly concordant (Pearson correlation >0.96). There was very strong reliability among pathologists in TC PD-L1 scoring with all assays (overall intraclass correlation coefficient [ICC] = 0.86-0.93), poor reliability in IC PD-L1 scoring (overall ICC = 0.18-0.19), and good agreement in assessing PD-L1 status on cytological cell block materials (ICC = 0.78-0.85). CONCLUSION: BP2 consolidates the analytical evidence for interchangeability of the 22C3, 28-8, and SP263 assays and lower sensitivity of the SP142 assay for determining tumor proportion score on TCs and demonstrates greater sensitivity of the 73-10 assay compared with that of the other assays.
引用
- Tsao MS, Kerr KM, Kockx M, et al. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. J Thorac Oncol. 2018. PMID: 29800747. doi:10.1016/j.jtho.2018.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。